PatientsHCP
This site is for US Health Care Professionals only.

What is the risk of waiting too long for biologic intervention?

Could HS be more severe than it appears?

In one study, nearly 45% of patients were reclassified to be moderate or severe* after an ultrasound exam (n=38)1†

Adapted with permission from Martorell A et al. Actas Dermosifiliogr. 2015. All rights reserved.2‡

Consider both the seen and unseen signs of HS when assessing disease severity1,2

 

First sign of moderate disease. Window of Opportunity. Tissue damage over time
Window of Opportunity. Starting COSENTYX within the window of opportunity-prior to the development of multiple irreversible tunnels and scarring-is thought to improve treatment outcomes.
Draining tunnels. Window of Opportunity. Tissue damage over time.
Irreversible scarring. Window of Opportunity. Tissue damage over time.
Irreversible scarring/disability. Window of Opportunity. Tissue damage over time.
HS takes a heavy toll on patients’ emotional and mental well-being

 
HS takes a heavy toll on patients’ emotional and
mental well-being
 

~97% of patients experience physical pain.6

~66% of patients experience depression.7 
>2x the risk of completed suicide in patients with HS compared with the general population.8

The impacts of HS are not limited only to those listed above.

Refer a Patient

Locate a dermatologist who specializes in the treatment of HS.

*As measured by patients going from Hurley Stage I to II or III.1
†Based on Spanish diagnostic study of adult patients diagnosed with HS (N=143). The number of patients who may have been reclassified to a lower Hurley stage was not reported/noted by the study. The mean number of fistulas on ultrasound compared to clinical exam was not statistically significant.1
‡Images are from a 2015 Martorell study, not the same study as the data presented above.2

Definition

HS, hidradenitis suppurativa.

References

1. Martorell A, Alfageme Roldán F, Vilarrasa Rull E, et al. Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicentre study. J Eur Acad Dermatol Venereol. 2019;33(11):2137-2142.
2. Martorell A, García-Martínez FJ, Jiménez-Gallo D, et al. An Update on Hidradenitis Suppurativa (Part I): Epidemiology, Clinical Aspects, and Definition of Disease Severity. Actas Dermosifiliogr. 2015;106(9):703-715.
3. Martorell A, Giovanardi G, Gomez-Palencia P, Sanz-Motiva V. Defining fistular patterns in hidradenitis suppurativa: impact on the management. Dermatol Surg. 2019;45(10):1237-1244.
4. Shih T, De D, Daveluy SD, et al. Real-world considerations of candidacy for biologics in hidradenitis suppurativa. Am J Clin Dermatol. 2022;23(6):749-753.
5. van der Zee HH, Zouboulis CC, Reguiai Z, et al. The impact of lesion type on clinical response with secukinumab in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the pooled data from SUNSHINE and SUNRISE phase 3 trials. Poster presented at 33rd European Academy of Dermatology and Venereology (EADV) Congress, September 25-28, 2024; Amsterdam, The Netherlands. Poster P0186.
6. Matusiak Ł, Szczȩch J, Kaaz K, Lelonek E, Szepietowski JC. Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa. Acta Derm Venereol. 2018;98(2):191-194.
7. McKenzie SA, Harview CL, Truong AK, et al. Physical symptoms and psychosocial problems associated with hidradenitis suppurativa: correlation with Hurley stage. Dermatol Online J. 2020;26(9):13030/qt4rm8w7kn.
8. Thorlacius L, Cohen AD, Gislason GH, Jemec GBE, Egeberg A. Increased suicide risk in patients with hidradenitis suppurativa. J Invest Dermatol. 2018;138(1):52-57.